Chemical Business Newsbase articles from April 2009

Chemical Business Newsbase archives from April 2009

MMC Norilsk Nickel announces preliminary consolidated production results for 1Q 2009.
April 30, 2009... OJSC MMC Norilsk Nickel, the world's largest nickel and palladium producer, announces preliminary consolidated production results for 1Q 2009 at its Polar and Kola Divisions in Russia and international operations in Finland, Australia,...

Praxair and Sorg to jointly promote glass-melting efficiency.
April 30, 2009... Praxair Inc has announced that it has signed a joint marketing agreement with Nikolaus Sorg GmbH & Co KG. Under the agreement, Praxair and Sorg will jointly promote high-efficiency oxy-fuel technology for glass melting in the US and Canada....

Fuwei Films announces expectations for 1Q 2009.
April 30, 2009... Fuwei Films (Holdings) Co Ltd announced its expectations regarding preliminary financial results of 1Q ended Mar 2009. Revenues for 1Q 2009 are expected to be approximately $11 M ($15.2 M in 1Q 2008). Net loss for 1Q 2009 is expected to be...

Texas Petrochemicals intends to rationalize C4 processing capacity - seeks $25 M in annual cost reductions and profit improvements.
April 30, 2009... Texas Petrochemicals Inc announced plans to enhance profitability and cash flow from its businesses by $25 M/y. To accomplish this objective, the company will utilize a combination of cost reductions and profit improvement initiatives during...

FDA approves Exforge HCT - the only high blood pressure treatment to combine three medications in a single pill.
April 30, 2009... The US Food and Drug Administration (FDA) has approved Exforge HCT (amlodipine, valsartan, hydrochlorothiazide), the only blood pressure (BP) treatment to combine three medications in a single pill. Exforge HCT combines the number one...

Woodward Labs reports sales spike for HandClens alcohol-free hand sanitizer during swine flu epidemic.
April 30, 2009... Woodward Laboratories, a leading antimicrobial skin care company and makers of HandClens the only alcohol-free instant hand sanitizer that exceeds the Food and Drug Administration's (FDA) effective testing standards for antiseptic hand...

Royer Animal Health enters into exclusive agreement with MWI Veterinary Supply for US distribution of next-generation therapeutics to treat cancer and infections.
April 30, 2009... Royer Animal Health LLC, a wholly owned subsidiary of Royer Biomedical, Inc, has executed an exclusive distribution agreement with MWI Veterinary Supply Inc to market its lead animal health products: Matrix III Cisplatin Beads and R-GEL...

Ingredient in probiotic sweetener boosts immune system.
April 30, 2009... Heartland Sweeteners LLC in conjunction with Ganeden Biotech has developed the world's first probiotic sweetener, Nevella with Probiotics, which is designed to boost the immune system and promote digestive health. Additionally, according to a...

Cystic Fibrosis - Orphan drug designation for innovative treatment against lung infections by Axentis Pharma AG.
April 30, 2009... An innovative treatment for infections of the respiratory tract in cystic fibrosis patients has received orphan drug designation in the US. Axentis Pharma of Zurich, Switzerland announced that this sought-after designation has been granted to...

Driven by sales of Enbrel, Remicade and Humira, spondyloarthropathies drug market grew to nearly $2 bn in 2008.
April 30, 2009... Decision Resources finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA) market, which reached...

Canadian study (VECTOR) presented at the 2009 American Urological Association Annual Meeting.
April 30, 2009... Patients with overactive bladder (OAB) treated with solifenacin reported significantly lower incidence and severity of dry mouth, an often intolerable anti-cholinergic side effect, than those treated with oxybutynin immediate-release (IR)....

AMDL Inc signs first customer agreement with Precision Diagnostic Laboratory for DR-70 (FDP) cancer test.
April 30, 2009... AMDL Inc has signed Precision Diagnostic Laboratory (PDL) Inc as its first customer to offer the AMDL DR-70 (FDP) in vitro cancer test to patients and doctors in the US. PDL Inc is a full-service, CAP (College of American Pathologists) and...

Alseres and BioAxone amend license agreement for Cethrin and Rho Inhibitor Technology.
April 30, 2009... Alseres Pharmaceuticals Inc announced that on 24 Apr 2009 it entered into an Amendment to License Agreement (Amendment) with BioAxone Therapeutic Inc (BioAxone), pursuant to which the license agreement between the company and BioAxone...

Study results published in CUTIS demonstrate long-term safety and efficacy of Vectical (calcitriol) Ointment 3 mcg/gm in the management of mild-to-moderate plaque psoriasis.
April 30, 2009... Galderma Laboratories LP announced results from a newly published clinical trial in Apr 2009 issue of CUTIS regarding the safety, tolerability and efficacy of Vectical (calcitriol) Ointment 3 mcg/g in the long-term management of...

Victhom and Otto Bock sign partnership agreement to establish joint venture for Neurobionix activities.
April 30, 2009... Victhom Human Bionics Inc (Victhom) and Otto Bock HealthCare GmbH (Otto Bock) announced the execution on 29 Apr 2009 of a partnership agreement to establish a joint venture to develop and commercialize products currently being developed by...

Arrayit to mass produce rapid H1N1 swine flu test chip.
April 30, 2009... Arrayit Corp is developing a microarray-based diagnostic test to detect the H1N1 swine flu virus. The Arrayit test will allow researchers and clinicians to detect the presence of the virus in infected patients and livestock and to distinguish...

Duramed launches LoSEASONIQUE oral contraceptive.
April 30, 2009... Duramed Pharmaceuticals announces the launch of its marketing campaign for LoSEASONIQUE (levonorgestrel/ethinyl estradiol tablets 0.10 mg/0.02 mg and ethinyl estradiol tablets 0.01 mg), a new low-dose extended-cycle oral contraceptive. It is...

Optherion Announces Issuance of Canadian Patents Covering Age-Related Macular Degeneration Diagnostics and Treatments.
April 30, 2009... Optherion Inc, announced that the Canadian Patent Office has granted patents 2,363,503 and 2,407,715. The claims of the issued patents provide secure protection for diagnostic tests for determining the predisposition to Age-related Macular...

Unexpected Positive Finding Expands Potential for Quigley QR333 Drug for Diabetic Neuropathy; findings suggest possible disease modification.
April 30, 2009... Quigley Pharma Inc, a wholly-owned subsidiary of The Quigley Corp announced that their recently completed Phase II double-blinded, placebo-controlled, clinical trial of diabetic peripheral neuropathy, demonstrated a significant improvement in...

Debiopharm Starts Phase IIb Study After Record Time Patient Randomisation.
April 30, 2009... Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, announced that on 7 Apr 2009 the last patient was randomised to take part in a...

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion.
April 30, 2009... Bayer HealthCare AG and Regeneron Pharmaceuticals Inc announced that the companies are extending their global development programme for VEGF Trap-Eye, an investigational agent for the treatment of certain eye diseases, to include Central...

Anthelios 60 Sunscreen with Cell-OX Shield available 1 May 2009 across the US.
April 30, 2009... La Roche-Posay proudly announces the availability of Anthelios 60 Sunscreen beginning 1 May 2009. A worldwide expert in UV protection, the brand's new revolutionary sunscreen range offers high UVA protection with Cell-OX Shield for protection...

Government nets GBP 387 M as nuclear auction ends.
April 30, 2009... The auction of sites for new nuclear power stations finally closed on 29 Apr 2009, netting the UK Government GBP 387 M and bringing a consortium of RWE, npower and E.ON into the UK sector for the first time. Two of the three sites owned by...

Market Report: Oxford BioMedica.
April 30, 2009... On 29 Apr 2009 Oxford BioMedica strengthened to 10.75p, up 16.2%, or 1.5p, after revealing that Sanofi Aventis, the French pharma group, had handed back rights to the TroVax therapeutic cancer vaccine, while at the same time entering into a...

Investment Column: Croda International.
April 30, 2009... Mike Humphrey, chief executive of the speciality chemicals company Croda, reported that the company's stock has been a decent performer, up nearly 10% in the last quarter before yesterday's first-quarter trading statement. And perhaps the shares...

Pill to treat MS unveiled.
April 30, 2009... A pill that effectively treats the most common form of multiple sclerosis (MS) could be available for the first time, it has been disclosed. The new treatment, cladribine, is a tablet form of a drug used to treat certain types of leukaemia....

Dabur's 4Q 2008-2009 consolidated net profit up28%.
April 30, 2009... Fast moving consumer goods firm Dabur India has recorded a 28% increase in consolidated net profit at Rup 105.25 crores on 21% higher net sales at Rup 736.3 crores for 4Q ended Mar 2009 (net profit of Rup 82.49 crores in 4Q ended Mar 2008)....

Apollo Tyres net profit down 21% for 4Q 2008-2009 on fall in demand.
April 30, 2009... Tyre manufacturer Apollo Tyres has recorded a 21% lower net profit at Rup 46.2 crores on net sales of Rup 1110 crores for 4Q ended Mar 2009 (net profit of Rup 59.2 crores on net sales of Rup 1001 crores in 4Q ended Mar 2008). The lower profit...

Piramal Glass: Results for 4Q 2008-2009.
April 30, 2009... Glass containers manufacturer Piramal Glass Ltd has incurred a net loss of Rup 2428 lakhs on net sales/income from operations of Rup 15,345 lakhs, on a stand alone basis, for 4Q ended Mar 2009 (net profit of Rup 409 lakhs on net sales/income...

Nagarjuna Fertilizers and Chemicals: Results for 4Q 2008-2009.
April 30, 2009... Fertilizers manufacturer Nagarjuna Fertilizers and Chemicals has recorded a net profit of Rup 1261.98 lakhs on net sales/income from operations of Rup 54,114.13 lakhs for 4Q ended Mar 2009 (net profit of Rup 125.66 lakhs on net sales/income...

L'Oreal takes to sachets: Ploy to gain market share, innovations high on agenda.
April 30, 2009... The French firm L'Oreal India has introduced its flagship brand Garnier, which consists of skin and hair care products, in sachets. Garnier shampoo sachets are priced at Rup 3/sachet and conditioner at Rup 4/sachet. The company has also...

Khimprom was put into bankruptcy procedure.
April 30, 2009... OAO Khimprom (Volgograd, Russia) is one of the largest chemical industrial complexes in Russia. It produces chemicals, chlorine organics, polymers, solvents and household chemicals. In 2007 its net losses were Roubles 266.5 M and from Jan to...

Pharmacy chain Zdorovye Ludi was sold.
April 30, 2009... GK Natur Produkt (NP, Russia) develops, produces and markets pharmaceuticals, vitamins and food additives. In 2008 its sales totalled $195 M. The retail group reported sales of $94 M. Recently NP sold its subsidiary pharmacy chain OOO...

Lupins biological pursuit.
April 30, 2009... Having made a mark in the generic markets, Lupin Pharma (Lupin) has now ventured into biologicals and is expecting about 40% of the future discoveries from biologicals. Lupin has taken a stride into the biologics market by making significant...

Biologics manufacturing on the rise.
April 30, 2009... The biologics business is growing rapidly in India with many companies like Shantha Biotechnics Ltd, Biocon, Intas Pharmaceuticals among others who are actively manufacturing biologics. Biologics include APIs and intermediates and vaccines....

Premas Biotech launches human drug metabolism enzymes.
April 30, 2009... Premas Biotech (Premas) has launched its range of recombinant human cytochrome P450 isozymes expressed in yeast. These microsomes are said to contain human CYP450 isozyme and human NADPH oxido reductase, which together contributes to its...

Launch of nine products in 2010 by Axygen Scientific.
April 30, 2009... Axygen Scientific (Axygen) has garnered total revenue of $110 M in 2008, of which 5.2% is derived from Asia Pacific region. Axygen has consolidated its presence in many segments including High throughput screening (HTS), PCR and reagents. HTS...

Demand for nitrogen fertilizers is saving Akron.
April 30, 2009... Akron Holding (Russia) is a large domestic nitrogen fertilizers producer. It recently reported results of its activities in 2008. Sales decreased by 16% to 4.75 M tonnes but receipts increased by 39% up to Roubles 43.1 bn. Net profit was...

Chelyabinsk zinc faces by low prices for zinc.
April 30, 2009... Chelyabinsk zinc plant (ChTsZ, Russia) is a large domestic zinc producer. Recently it reported its financial results for 2008. Sales were Roubles 9.97 bn (-36% compared to 2007). Net losses were Roubles 3.52 bn, EBITDA was Roubles 10 M only...

Highland Gold sold gold field at Chukotka.
April 30, 2009... Highland Gold Mining (HGM, UK) reported that it has sold the Maiskoe gold project in Chukotka (Russia) to Polimetal and 4 private investors, for $105 M but HGM will gain currency of $150,000 only. Maiskoe gold field is one of the five largest...

Pharmacy chain 36.6 changed report for 2007 post factum.
April 30, 2009... Aptechnaya set 36,6 (Pharmacy chain 36.6, Russia) is the largest domestic pharmacy chain. Recently it reported financial results of 2008 activities. Sales increased by 20.7% to $1.5 bn, net losses decreased by 54% to 56.4 M. Such positive...

Directive 2009/35/EC OF The European Parliament and of The council of 23 Apr 2009 on the colouring matters which may be added to medicinal products. [one table in original].
April 30, 2009... Council Directive 78/25/EEC of 12 Dec 1977 on the approximation of the laws of the Member States relating to the colouring matters which may be added to medicinal products has been substantially amended several times. The primary purpose of...

Commission Decision of 28 Apr 2009 authorising the placing on the market of lycopene oleoresin from tomatoes as novel food ingredient under Regulation (EC) No 258/97 of the European Parliament and of the Council.
April 30, 2009... On 7 Sep 2004 the company Ottaway & Associates Ltd on behalf of the company LycoRed made a request to the competent authorities of the UK to place lycopene oleoresin from tomatoes on the market as a novel food ingredient; on 30 Jun 2005 the...

New flame retardant from Lanxess for wood: Protects natural materials for construction and furniture industries.
April 30, 2009... Disflamoll TP LXS 51064, developed by the specialty chemicals group Lanxess AG, is a state-of-the-art flame retardant for use in wood and wood related products. The flame-retardant properties of organic phosphorus compounds turn a large...

Lubrizol's new HyperZDP system protects engine, catalyst and the environment.
April 30, 2009... On 30 Apr 2009, The Lubrizol Corp introduced its new HyperZDP System-a patented lubricant additive technology delivering an ideal balance between extended catalyst system life and engine wear protection. The HyperZDP System offers a distinct...

Commencement of oil production from West Don field.
April 30, 2009... On 30 Apr 2009, Nippon Oil Corp announced today that Nippon Oil Exploration and Production UK Ltd commenced commercial oil production on 28 Apr 2009 from West Don field in the UK North Sea. NOEPUK is owned by Nippon Oil Exploration Ltd, which...

Occidental Petroleum announces dividend increase.
April 30, 2009... On 30 Apr 2009, Occidental Petroleum Corp announced that its Board of Directors has increased the company's quarterly dividend from $.32 per share to $.33 per share for an annual rate of $1.32 per share, compared to the previous annual rate...

Bayer: demand for plastics reached rock bottom. Results in 1Q 2009.
April 30, 2009... German chemicals group Bayer generates around 30% of group turnover with plastics. Turnover by the plastics division decreased by 35% in 1Q 2008. The net operating result for this segment fell to minus EUR 116 M (plus EUR 407 M in 1Q 2008)....

Continental affected by the crisis in the automotive industry.
April 30, 2009... German company Continental (supplier to the automotive industry) has been affected by the global fall in demand experienced by the automotive industry. Turnover decreased by more than a third to EUR 4.3 bn in 1Q 2009. Despite the largest...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Initial applications for marketing authorisation: New medicinal products.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) adopted four positive opinions by consensus on initial marketing authorisation applications for new medicinal...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Initial applications for marketing authorisation: Generic medicinal products.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions by consensus on initial marketing authorisation applications for generic medicinal...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Initial applications for marketing authorisation: Re-examination procedure under Article 9(2) of Regulation (EC) No. 726/2004 started.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) announced that it has been formally requested by Gilead Sciences International Ltd to re-examine the negative...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Initial applications for marketing authorisation: Withdrawals.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) announced that it has been formally notified by Teva Pharma BV of its decision to withdraw its application for a...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Post-authorisation procedures: Extensions of indication and other recommendations.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) gave nine positive opinions by consensus for applications for the extension of indication, adding a new...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Post-authorisation procedures: Addition of warning.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) adopted an amendment to update sections 4.4 and 4.5 of the Summary of Product Characteristics (SPC) for Doribax...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Post-authorisation procedures: Other information.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) adopted several amendments to update sections 4.4 and 4.8 of the SPC for Tarceva (erlotinib) from Roche...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Post-authorisation procedures: Abacavir and the risk of heart attack.
April 30, 2009... Finalising a review of recent data on the risk of heart attack (myocardial infarction) associated with the use of abacavir in HIV-infected patients, at its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Referral procedures: Referral procedures concluded.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) concluded two referral procedures under Article 29 of Directive 2001/83/EC, as amended. This type of procedure...

Committee for Medicinal Products for Human use Apr 2009 plenary meeting monthly report: Referral procedures: Referral procedures started.
April 30, 2009... At its meeting of 20 to 23 Apr 2009, the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) started a referral procedure under Article 31 of Regulation (EC) 83/2001, as amended for valproate-containing...

Bigger loss for PCI Biotech in 1Q 2009.
April 30, 2009... PCI Biotech, Norway, recorded a pretax result of NKR -4.4 M for 1Q 2009, compared with NKR -3.5 M for 1Q 2008. Operating income was up from NKR 1.6 M to NKR 1.7 M. The company says it will continue to focus on supplying pharmaceuticals based...

FDA requires boxed warning for all botulinum toxin products.
April 30, 2009... On 30 May 2009, prompted by reports of serious adverse events, the US Food and Drug Administration announced that safety label changes, including a boxed warning, and a Risk Evaluation and Mitigation Strategy (REMS), are necessary for all...

AstraZeneca 1Q 2009: Financial Summary.
April 30, 2009... AstraZeneca's sales for 1Q 2009 increased by 7% at constant exchange rates (CER) to $7701 M. Core operating profit increased by 19% at CER to $3362 M. The core operating margin improved on sales growth, operational efficiencies, higher other...

AstraZeneca 1Q 2009: Gastrointestinal sales.
April 30, 2009... For 1Q 2009, AstraZeneca's Gastrointestinal sales totalled $1427 M, at constant exchange rates (1Q 2008: $1510 M). Key financial data are tabulated. Sales of Nexium totalled $1192 M (1Q 2008: $1238 M), with sales of Losec/Prilosec at $211 M...

AstraZeneca 1Q 2009: Cardiovascular sales.
April 30, 2009... For 1Q 2009, AstraZeneca's Cardiovascular sales totalled $1810 M, at constant exchange rates (1Q 2008: $1571 M). Key financial data are tabulated. Sales of Crestor totalled $969 M (1Q 2008: $772 M), with sales of Seloken/Toprol-XL at $288 M...

AstraZeneca 1Q 2009: Respiratory and Inflammation sales.
April 30, 2009... For 1Q 2009, AstraZeneca's sales of Respiratory and Inflammation products totalled $935 M, at constant exchange rates (1Q 2008: $1040 M). Key financial data are tabulated. Sales of Symbicort totalled $515 M (1Q 2008: $471 M), with sales of...

AstraZeneca 1Q 2009: Oncology sales.
April 30, 2009... For 1Q 2009, AstraZeneca's sales of Oncology products totalled $1083 M, at constant exchange rates (1Q 2008: $1165 M). Key financial data are tabulated. Sales of Arimidex totalled $463 M (1Q 2008: $430 M), with sales of Casodex at $236 M (1Q...

AstraZeneca 1Q 2009: Neuroscience sales.
April 30, 2009... For 1Q 2009, AstraZeneca's sales of Neuroscience products totalled $1432 M, at constant exchange rates (1Q 2008: $1378 M). Key financial data are tabulated. Sales of Seroquel amounted to $1125 M (1Q 2008: $1050 M) and Zomig sales totalled...

AstraZeneca 1Q 2009: Infection and other sales.
April 30, 2009... For 1Q 2009, AstraZeneca's sales of anti-infectives and other products totalled $792 M, at constant exchange rates (1Q 2008: $787 M). Key financial data are tabulated. Sales of Synagis were up 5% to $545 M, with Merrem sales at $202 M (+8%)...

AstraZeneca 1Q 2009: Geographic sales.
April 30, 2009... For 1Q 2009, AstraZeneca reported sales of $7701 M at constant exchange rates (CER), 7% higher than for 1Q 2008. North America accounted for $3891 M of sales (1Q 2008: $3723 M), with sales in the US at $3624 M (1Q 2008: $3401 M). Sales in...

UCB 1Q 2009: focuses on new product launches.
April 30, 2009... On 30 Apr 2009 UCB announced its interim report for 1Q 2009. Revenue decreased compared to 1Q 2008 due to a lower net sales contribution from the US market. Recurring EBITDA and net profit performance were in line with the company's...

UCB's CEO statement at AGM: UCB executing on its strategy: FY 2008 and 1Q 2009.
April 30, 2009... At UCB's Annual General Meeting on 30 Apr 2009 the group's Chief Executive Officer gave shareholders an overview of the financial year 2008 and the interim report for 1Q 2009. The CEO also confirmed the company's plans to become the next...

Unifi announces 3Q 2008-2009 results.
April 30, 2009... Unifi Inc released preliminary operating results for its 3Q ended 29 Mar 2009. Net sales for 3Q 2008-2009 were $119.1 M (-$50.7 M from net sales of $169.8 M in 3Q 2007-2008). Net sales were negatively impacted by the cumulative effect of...

EnPro Industries announces 1Q 2009 results.
April 30, 2009... EnPro Industries Inc reported net income of $3.2 M or $0.16/share for 1Q ended Mar 2009 (net income of $12.5 M or $0.58 a share in 1Q 2008). The company's sales decreased by 24% to $216.4 M for 1Q 2009 ($283.1 M in 1Q 2008). Earnings before...

Medarex announces 1Q 2009 financial results.
April 30, 2009... Medarex Inc announced its financial results for the 1Q ended 31 Mar 2009. Medarex's net income for 1Q 2009 was $48.6 M or $0.38/share (net income for 1Q 2008 was $103.3 M or $0.81/share). Total revenues for 1Q 2009 were $10.8 M (total...

Nuvo announces 1Q 2009 financial results.
April 30, 2009... Nuvo Research Inc, a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, announced its financial...

Newmont generates 1Q 2009 net cash from continuing operations of $387 M ($0.82/share); maintaining 2009 outlook.
April 30, 2009... Newmont Mining Corp (Newmont) announced 1Q ended 31 Mar 2009 results, with net cash from continuing operations of $387 M ($0.82/share) with equity gold sales of 1.27 M ounces at an average realized gold price of $906/ounce. Costs applicable...

Marathon Oil Corp reports 1Q 2009 results.
April 30, 2009... Marathon Oil Corp (Marathon) reported 1Q ended 31 Mar 2009 net income of $282 M or $0.40/diluted share ($731 M or $1.02/diluted share in 1Q 2008). Revenues and other income were $10.35 bn in 1Q 2009 ($18.10 bn in 1Q 2008). Additionally,...

CARBO Ceramics Inc announces 1Q 2009 earnings.
April 30, 2009... CARBO Ceramics Inc announced financial results for 1Q ended 31 Mar 2009. The company reported a net income of $16.4 M or $0.70/basic and diluted share, on revenues of $90.6 M for 1Q 2009 (a net income of $14.2 M or $0.58/basic and diluted...

Lubrizol announces earnings of $0.95/share for 1Q 2009.
April 30, 2009... The Lubrizol Corp announced that consolidated earnings for 1Q ended Mar 2009 were $64.2 M, or $0.95/diluted share, including after-tax restructuring charges of $7.6 M, or $0.11/diluted share (earnings for 1Q 2008 were $73.6 M, or...

P&G reports 3Q 2008-2009 organic sales, EPS and cash flow growth.
April 30, 2009... The Procter & Gamble Co (P&G) announced diluted net earnings/share (EPS) of $0.84, up 2% for 3Q ended Mar 2009 and toward the high end of the company's guidance for the quarter. Core EPS, which excludes the net impact from the sale of the...

Dow reports 1Q 2009 results.
April 30, 2009... The Dow Chemical Co reported sales of $9.1 bn for 1Q ended Mar 2009, 39% lower than in 1Q ended 2008. Net income for 1Q 2009 was $24 M (net income of $941 M in 1Q 2008). Reported earnings for 1Q 2009 were $0.03/share (earnings of $0.99/share in...

Ashland Inc reports preliminary net income of 65 cts/share for 2Q 2008-2009.
April 30, 2009... Ashland Inc announced preliminary results for 2Q and 1H ended Mar 2009. Ashland's results for 2Q 2008-2009 were as follows: sales and operating revenues of $1990 M; and net income of $48 M, or 65 cts/share. Ashland Aqualon Functional...

Osteotech reports 1Q 2009 financial results.
April 30, 2009... Osteotech Inc reported financial results for 1Q ended Mar 2009. Recent 2009 corporate developments are included in the report. Revenue for 1Q 2009 was $23.9 M ($27.6 M in 1Q 2008). The decline in 1Q 2009 revenue compared with 2008 was...

CRH Medical reports year end results.
April 30, 2009... CRH Medical Corp recorded revenues of $6,655,342 for the year ended Dec 2008 ($3,245,690 in year ended Dec 2007). Clinic operations revenue increased 100% to $6,047,590 for 2008 ($3,023,558 in 2007). Product sales increased 173% to $607,752...